China’s Zai Lab (Nasdaq: ZLAB), a Shanghai-based innovative biopharmaceutical company, has appointed that William Liang as chief commercial officer, reporting to Dr Samantha Du, Zai Lab’s chief executive.
Mr Liang brings more than two decades of experience in the pharmaceutical industry, heading China and regional commercial operations of global companies, with expertise in commercial launch, strategy and operations.
He was instrumental in establishing market-leading oncology and other franchises in China for AstraZeneca (LSE: AZN) and Roche (ROG: SIX), overseeing commercial success of top selling drugs for the two pharma majors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze